All News

RheumNow Podcast square

RheumNow Podcast - Best of EULAR 2021

Jack Cush, MD

Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.

Read Article
DAPSA PsA measure

Q-DAPSA for Measuring Disease Activity in PsA

Rachel Tate, DO

Given its multiple domains, there remains much discussion over the best disease activity scoring method in PsA. The proverbial "holy grail" would be a measure that is quick, intuitive, domain comprehensive and validated.

Read Article
audience learn

EULAR 2021 - Day 3 Report

Jack Cush, MD

Here are a few notable presentations from this past Friday, Day 3 of the EULAR 2021 virtual meeting.

Read Article
PSA068.jpg

Novel TYK2 Inhibitor Efficacious for Treatment of Psoriatic Arthritis

Meral K. El Ramahi, MD, FACP, FACR

Dr. Philip Mease et al presented results of a phase II trial (OP0227) at EULAR 2021 that shows the efficacy and safety of an oral tyrosine kinase inhibitor (TYKi), deucravacitinib, for treatment of active psoriatic arthritis (PsA).

Read Article
unhappy%20patient.jpg

How do we personalize psoriatic arthritis treatment?

Robert Chao, MD

It seems like every conference we are presented with data on the newest biologic for treatment of psoriatic arthritis, but the question is, do we need it?

Read Article
COVID vaccine vials

Israel provides COVID vaccine answers for rheumatic disease patients

David Liew, FRACP

The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheumatologists’ offices everywhere this year, and at the EULAR 2021 Virtual Congress, data presented from Israel, one of the first countries to vaccinate on a br

Read Article
How do we personalize psoriatic arthritis treatment? Dr. Robert Chao ( @doctorRBC ) discusses presentation 6937 from #EULAR2021. https://t.co/1d9IsSqr0n https://t.co/ZbHwdWimgL

Links:

Dr. John Cush RheumNow ( View Tweet)
Video: Treatment Options for PsA Patients: Dr. Paul Studenic Dr. Paul Studenic reviews highlights from three PsA abstracts - abstract op0227, abstract op0229, and abstract op0233 - presented at the virtual #EULAR2021 meeting. https://t.co/QlquUQFQOJ https://t.co/p5wBTboIpE

Links:

Dr. John Cush RheumNow ( View Tweet)
Psoriatic arthritis mortality & morbidities by Dr. Paul Studenic #EULAR2021 PsA is a chronic condition with manifold clinical presentations. Health issues may be far beyond the classical associated conditions like uveitis, enthesitis etc. https://t.co/zHfeaiiG93 https://t.co/AoHenH6YkK

Links:

Dr. John Cush RheumNow ( View Tweet)
Video: The PsA SpA Paradox of Choice Dr. Rachel Tate ( @uptoTate) reviews Dr. Laura Coates' presentation Personalized Treatment Strategies in Psoriatic Arthritis, given at the virtual #EULAR2021 meeting. https://t.co/Yg12SHR1MF https://t.co/UiCYDU5XGc

Links:

Dr. John Cush RheumNow ( View Tweet)
New GRAPPA 2021 PsO and PsA Treatment Recommendations by Dr. Rachel Tate ( @uptotate) The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021. Read more... https://t.co/AnHQGA8aKs https://t.co/4c18j4h54T

Links:

Dr. John Cush RheumNow ( View Tweet)
Video: Personalization of PsA Treatment: Dr. Robert Chao ( @doctorRBC) Dr. Robert Chao reviews a talk given by Dr. Laura Coates entitled, "Towards personalized treatment strategies for psoriatic arthritis", presented #EULAR2021. https://t.co/LeocvUyZ7N https://t.co/g6ApPL0Pui

Links:

Dr. John Cush RheumNow ( View Tweet)
#EULAR2021 - Day 3 Report https://t.co/X7zxsKW8eL https://t.co/OKu5Mgodlo

Links:

Dr. John Cush RheumNow ( View Tweet)
@IainBMcInnes1 @NEJM @JWatch @NEJMres360 #rheumatology #rheumtwitter #MedTwitter #VisualAbstract #WorldASDay #spondyloarthritis #psoriasis #psoriaticarhtritis #MedEd #dermatology #JAKi #EBM https://t.co/dGRi83Wt9x https://t.co/22WacHQZpT

Links:

EnvisionRheumat ERheumat ( View Tweet)
➡️Netakimab = IL17Ai approved for AS, PsA, & Pso in Russia & Belarus

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

⭐️JUNIPERA: RCT of SEC in active ERA & JPsA (2-18yo, most on MTX) -Tx . (TP)1: SEC 75/100 mg till wk 12 -TP2: cont SEC or switch to PBO till wk 104 ⭐️SEC efficacious on JIA ACR30/70 ⭐️74% w/ resolution of enthes ⭐️Median T2flare in PBO in TP2 = 453d LB0004 #EULAR2021 @Rheumnow https://t.co/JsG2pXz9r6
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
No clear winner here. The majority would use #IL23 inhibitors as either 2nd or 3rd line bDMARDs and for #psoriaticarthritis with severe #psoriasis. Thank you for participating in the polls #EULAR2021 @RheumNow https://t.co/b8wzaRVTqw

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)

6. Rheum disease activity was stable with COVID vaccination. (RA, PsA, axSpA, SLE - total n = 597) 7/ LB0003 #EULAR2021 @RheumNow https://t.co/xxkrunjPa0
David Liew drdavidliew ( View Tweet)
I write more about this for @RheumNow - it’s powerful to know that AI can accurately tell the difference between RA, PsA, and healthy controls on the basis of the bony surface at MCP 2: https://t.co/ChDfihnW4f @LkasDer @maier_ak @FAU_Germany OP0145 #EULAR2021 (ping @DrCMcMaster) https://t.co/Pl7yxYfEqr

Links:

David Liew drdavidliew ( View Tweet)

#OP0223 US disease activity and damage score for PsA - ~300 patients from 19 centres - 6 components for disease activity score & 5 for damage -->~90% variability explained --> weighted score -->many sites to scan --> evaluation as BL pred. for MDA #EULAR2021 @RheumNow https://t.co/5kC6YDQi8D
Paul Studenic Stiddyo ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×